SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1284Topics in Adult Primary Care - Insomnia Expert Column Message 20740837Icebrg-11/6/2004
1283Neurocrine Biosciences "hold," estimates reduced Tuesday, November 02Icebrg-11/2/2004
1282Modest Near-Term Upside Seen For Neurocrine 11.02.04, 4:01 PM ET Morgan StanleyIcebrg-11/2/2004
1281“high risk; high reward; not a chance in hell" (I second Fred) Rickscaram(o)uche-11/1/2004
1280Hey Sales: I'm way overdue in saying thanks for your posts. But if I posted fred hayes-11/1/2004
1279Since the website hasn’t been updated in a long while, I thought I’d organize thsoftware salesperson-11/1/2004
1278<<* A development compound from the melanocortin-4 receptor (MC-4) technolMiljenko Zuanic-11/1/2004
1277>>SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.tuck-11/1/2004
1276SSB: NBIX: Submits U.S. Filing for Indiplon IR Formulation in Line with Expectatmopgcw-10/26/2004
1275NBIX mystery for me is the slow, non-existent in fact, flow of results from the quidditch-10/26/2004
1274Takeda drug isn't considered a serious threat.rkrw-10/26/2004
1273One question is how/who will market for them in the US?mopgcw-10/26/2004
1272re Indiplon -here is a competitive product from Takeda September 24, 2004 TakedSpekulatius-10/26/2004
1271Curr Med Chem Cardiovasc Hematol Agents. 2004 Jan;2(1):43-7. Related Articles,LiBiomaven-10/25/2004
1270<<Urocortin 2 has a novel mechanism of action. Based on our preclinical efMiljenko Zuanic-10/25/2004
1269<i>We expect two additional compounds to enter clinical trials before yearkeokalani'nui-10/25/2004
1268Neurocrine Biosciences Announces Initiation of Phase I Trial With Urocortin 2 foscaram(o)uche-10/25/2004
1267Pharmacopeia Announces Expanded Collaboration With Neurocrine Monday October 25,Icebrg-10/25/2004
1266I wonder if anyone has bothered asking Pfizer about the Class I versus Class II tuck-10/20/2004
1265Neurocrine Submits New Drug Application (NDA) for Indiplon Immediate Release Capnigel bates-10/19/2004
1264With all the recent focus on Indiplon, I thought it might be time to have a looktuck-10/17/2004
1263Neurocrine Biosciences initiated with "market perform" Wednesday, OctIcebrg-10/14/2004
1262Pharmacopeia Delivers Leads and Triggers Research Milestone in Collaboration witIcebrg-9/27/2004
1261Takeda Submits New Drug Application for Ramelteon, an Investigational Sleep DrugIcebrg-9/24/2004
1260High Expectations For Neurocrine's Insomnia Drug 09.09.04, 11:33 AM ET CrIcebrg-9/22/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News